Penicillin, ampicillin and cephaloridine in severe exacerbations of purulent chronic bronchitis in elderly patients

doi:10.1016/0007-0971(71)90010-6

British Journal of Diseases of the Chest

Volume 65, 1971, Pages 91-97

https://doi.org/10.1016/0007-0971(71)90010-6 Get rights and content

Abstract

Three antimicrobial regimens were compared in elderly patients with severe purulent exacerbations of chronic bronchitis. These were cephaloridine 4·5 and 6 g daily, benzyl penicillin nine million and then six million units daily and ampicillin 4 g daily by mouth with an initial supplement of 3 g daily intramuscularly, each for 14 days.

The benzyl penicillin regimen was inferior and had to be withdrawn. Cephaloridine 6 g daily was marginally superior to the ampicillin regimen but not cephaloridine 4·5 g daily. Overt untoward effects were few, though casts in the urine with cephaloridine 6 g daily were common. Cephaloridine 6 g daily seemed to be an effective antimicrobial agent in elderly subjects with troublesome purulent chronic bronchitis. It should be considered especially when more ordinary treatments have failed. Despite its slight inferiority, circumstances might sometimes make the ampicillin regimen described preferable because only few injections were needed.

References (19)

K.M. Citron et al.
Cephaloridine compared with penicillin and streptomycin in exacerbations of chronic mucopurulent bronchitis
Lancet
(1968)
D.O. Lewis et al.
Treatment of exacerbations of bronchitis with high dosage penicillin and with penicillin plus streptomycin
Brit. J. Dis. Chest
(1965)
A. Pines
Four trials of antibiotics in patients with chronic mucopurulent bronchitis
Postgrad. med. J.
(1967)
A. Pines et al.
Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis
Brit. med. J.
(1968)
O.L. Wade
In discussion, The chemotherapy of infections
Postgrad. med. J.
(1967)
M. Barber et al.
Penicillin-resistant penicillins and cephalosporins
Brit. med. J.
(1964)
J. Crofton
Some principles in the chemotherapy of bacterial infections
Brit. med. J.
(1969)
J.W. Crofton et al.
Respiratory Diseases
(1969)
P.C. Elmes et al.
Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis
Brit. med. J.
(1965)

There are more references available in the full text version of this article.

Cited by (8)

One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD)-Republished article
2008, Respiratory Medicine: COPD Update
COPD is an increasing health problem and one of the leading causes of morbidity and mortality worldwide, but knowledge about its pathogenesis has increased substantially in recent years. The disease results from interaction between individual risk factors (like enzymatic deficiencies) and environmental exposures to noxious agents, like cigarette smoking, occupational dusts, air pollution and infections in childhood. The main mechanisms that may contribute to airflow limitation in COPD are fixed narrowing of small airways, emphysema and luminal obstruction with mucus secretions. COPD is characterized by a chronic inflammatory process in the pulmonary tissue, with a pattern different from bronchial asthma, associated with extra pulmonary effects and is considered now a complex, systemic disease. Optimal therapeutic targeting of COPD depends on a clear understanding of the precise mechanisms of these complex processes and on early and correct evaluation of disease severity. A combination of pharmacological and non-pharmacological approaches is used to treat COPD. Bronchodilators are the mainstay of COPD treatment and can be combined with inhaled corticosteroids for greater efficacy and fewer side effects. The use of LTOT for hypoxemic patients has resulted in increased survival, and expanded drug therapy options have effectively improved dyspnoea and quality of life. Recent studies have documented the benefits of pulmonary rehabilitation. In addition, noninvasive mechanical ventilation offers new alternatives for patients with acute or chronic failure.
One hundred years of chronic obstructive pulmonary disease (COPD)
2007, Respiratory Medicine
Citation Excerpt :
Unfortunately, during the ensuing decades, penicillin-resistant pneumococci has become an area for great clinical concern worldwide because it has been associated with treatment failure. Up to 1980, the journal published a large amount of papers105–128 on the use of antibiotics in the treatment or prophylaxis of acute exacerbation of chronic bronchitis. In effects, at that time there was a lot of interest for the antibiotic therapy.
Chronic obstructive pulmonary disease (COPD) is an increasing health problem and one of the leading causes of morbidity and mortality worldwide, but knowledge about its pathogenesis has increased substantially in recent years. The disease results from interaction between individual risk factors (like enzymatic deficiencies) and environmental exposures to noxious agents, like cigarette smoking, occupational dusts, air pollution and infections in childhood. The main mechanisms that may contribute to airflow limitation in COPD are fixed narrowing of small airways, emphysema and luminal obstruction with mucus secretions. COPD is characterised by a chronic inflammatory process in the pulmonary tissue, with a pattern different from bronchial asthma, associated with extrapulmonary effects and is considered now a complex, systemic disease. Optimal therapeutic targeting of COPD depends on a clear understanding of the precise mechanisms of these complex processes and on early and correct evaluation of disease severity. A combination of pharmacological and non-pharmacological approaches is used to treat COPD. Bronchodilators are the mainstay of COPD treatment and can be combined with inhaled corticosteroids for greater efficacy and fewer side effects. The use of LTOT for hypoxemic patients has resulted in increased survival, and expanded drug therapy options have effectively improved dyspnoea and quality of life. Recent studies have documented the benefits of pulmonary rehabilitation. In addition, non-invasive mechanical ventilation offers new alternatives for patients with acute or chronic failure.
The Cephalosporin Group of Antibiotics
1975, Advances in Pharmacology
This chapter discusses the cephalosporin group of antibiotics. Two sites in the cephalosporin molecule are: (1) the 7-acyl side chain, leading to the production of 7-acylaminocephalosporanic acids—for example, ring-substituted phenylacetylcephalosporanic acids (analogous to benzylpenicillin) and ring-substituted phenoxyacetylcephalosporanic acids members of both types being active mainly against gram-positive bacteria, and (2) the 3-acetoxymethyl side chain leading to the production of deacetylcephalosporins and deacetoxylcephalosporins. The former have about half the activity of the parent compounds against gram-positive bacteria, such as staphylococci, but much reduced activity against gram-negative bacteria. Removal of the acetoxy group gives 3-hydroxyl derivatives,which are less antibacterial than the parent acetoxy compounds. Cephalosporin C, cephalothin, and cephaloglycin all lose antibacterial activity rapidly when incubated with rat liver homogenate, because of removal of the acetoxy group; however, cephaloridine and cephalexin do not possess these labile ester linkages and are thus, not inactivated.
Chloramphenicol and ampicillin compared in elderly patients with severe purulent exacerbations of bronchitis
1972, British Journal of Diseases of the Chest
Two hundred elderly patients with severe purulent exacerbations of chronic bronchitis were given either ampicillin or chloramphenicol by random allocation. Both antibiotics were given in high doses and with intramuscular supplements. Significant advantages appeared for chloramphenicol during the treatment of the actual exacerbation, but the relapse rate was equal over the subsequent month's observation in patients treated with either antibiotic regimen. Untoward effects were much less with chloramphenicol. Chloramphenicol should be considered as a first choice antibiotic in the treatment of elderly patients suffering from severe exacerbations of chronic bronchitis.
Role of Infection in Chronic Bronchitis
1975, New England Journal of Medicine
Five-day Wards in 1974
1974, British Medical Journal

View all citing articles on Scopus

View full text

General articlePenicillin, ampicillin and cephaloridine in severe exacerbations of purulent chronic bronchitis in elderly patients

Abstract

Lancet

Brit. J. Dis. Chest

Postgrad. med. J.

Brit. med. J.

Postgrad. med. J.

Penicillin-resistant penicillins and cephalosporins

Brit. med. J.

Some principles in the chemotherapy of bacterial infections

Brit. med. J.

Respiratory Diseases

Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis

Brit. med. J.

General article
Penicillin, ampicillin and cephaloridine in severe exacerbations of purulent chronic bronchitis in elderly patients